Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles

Producción científica: Article › revisión exhaustiva

15 Citas (Scopus)

Resumen

Nanoparticles are widely used as drug carriers for controlled, tumor-targeted delivery of various anticancer agents that have biopharmaceutical limitations such as water solubility and tissue permeability. Growing evidence suggests that nanoparticles not only reduce toxic side effects of anticancer drugs but also improve the therapeutic efficacy as a function of their drug-release profile. The purpose of this study is to confirm such hypothetical effects of tunable drug release on improving antitumor activity of nanoparticles in vitro and in vivo, using block copolymer micelles as drug carriers. Micelles were prepared from poly(ethylene glycol)-poly(aspartate) block copolymers modified with hydrazide (HYD), aminobenzoate hydrazide (ABZ) and glycine hydrazide (GLY) linkers to achieve a pH-dependent, tunable release of doxorubicin (DOX), a model anticancer drug. Regardless of the drug-release profile, all three micelles showed similar properties in vitro, such as pH-dependent drug release, intracellular drug delivery and cancer cell growth inhibition. However, micelles releasing DOX slowly in vitro showed that the most effective antitumor activity in vivo, compared to the micelles releasing drugs faster. These results demonstrate that tumor-preferential sustained drug release can enhance the antitumor activity of the micelles.

Idioma originalEnglish
Páginas (desde-hasta)619-628
Número de páginas10
PublicaciónJournal of Drug Targeting
Volumen22
N.º7
DOI
EstadoPublished - ago 2014

Nota bibliográfica

Funding Information:
The authors report no declarations of interest. This study was supported by the Kentucky Lung Cancer Research Program. The authors acknowledge Dr Pengxiao Cao for his technical support in performing the in vivo study.

Financiación

The authors report no declarations of interest. This study was supported by the Kentucky Lung Cancer Research Program. The authors acknowledge Dr Pengxiao Cao for his technical support in performing the in vivo study.

Financiadores
Kentucky Lung Cancer Research Program

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Pharmaceutical Science

    Huella

    Profundice en los temas de investigación de 'Tumor-preferential sustained drug release enhances antitumor activity of block copolymer micelles'. En conjunto forman una huella única.

    Citar esto